Medicare Part B (Medical Insurance) covers FDA-authorized COVID-19 monoclonal antibody treatments and products, if all of these apply:
- You tested positive for COVID-19.
- You have a mild to moderate case of COVID-19.
- You’re at high risk of progressing to a severe case of COVID-19 and/or at high risk of requiring hospitalization.
Your costs in Original Medicare
You pay nothing for a monoclonal antibody treatment during the COVID-19 public health emergency (and for the rest of the calendar year in which the COVID-19 public health emergency ends in which the Emergency Use Authorization (EUA) for this treatment ends) when you get it from a Medicare provider or supplier. In the calendar year after the EUA ends, Original Medicare will cover monoclonal antibody treatments if you have COVID-19 symptoms.
What it is
If you test positive for COVID-19 and have mild to moderate symptoms, these treatments can help fight the disease and keep you out of the hospital. This treatment involves an infusion of monoclonal antibodies (specifically bamlanivimab, or casirivimab and imdevimab) to treat COVID-19. Health care providers can only give the infusions in certain settings.